Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344765 | 0.94 | PAX8 (0.46) | TSHRPAX8PTPN1PRKCAAKT1 | |
| SCHEMBL14199422 | 0.94 | TSHR (0.48) | TSHRPAX8PRKCAAKT1PTK2 | |
| SCHEMBL17850340 | 0.93 | TSHR (0.55) | TSHRPAX8PTPN1USP2MEN1 | |
| SCHEMBL17850321 | 0.93 | TSHR (0.55) | TSHRPAX8PTPN1USP2MEN1 | |
| SCHEMBL13447782 | 0.93 | TSHR (0.55) | TSHRPAX8PTPN1USP2MEN1 | |
| SCHEMBL19102399 | 0.92 | TSHR (0.47) | TSHRPAX8PTPN1PRKCAAKT1 | |
| SCHEMBL20023215 | 0.92 | TSHR (0.47) | TSHRPAX8PTPN1PRKCAAKT1 | |
| SCHEMBL16298992 | 0.92 | TSHR (0.47) | TSHRPAX8PTPN1PRKCAAKT1 | |
| SCHEMBL22022529 | 0.92 | TSHR (0.53) | TSHRPAX8PTPN1USP2MEN1 | |
| SCHEMBL13702187 | 0.91 | TSHR (0.47) | TSHRPAX8PTPN1USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240209372-A1 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-11840692-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230323363-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-10-12 | — | — | US | disclosed |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230310485-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230203486-A1 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230183707-A1 | COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230133147-A1 | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-05-04 | — | — | US | disclosed |
| US-20230126881-A1 | Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-01-13 | — | — | US | disclosed |
| US-20170304459-A1 | METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE | ALNYLAM PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2016030863-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310485-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | AGT, AGTR1, AGTR2 | TSHR 1349/4885PAX8 3462/4885PTPN1 1239/4885 |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAF6, TRAF2, TNFRSF1A | TSHR 2737/4885PAX8 1857/4885PTPN1 2090/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | TSHR 2751/4885PAX8 2528/4885PTPN1 1440/4885 |
| US-20170304459-A1 | METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE | SLCO2B1, SLCO2A1, CHRM3 | TSHR 1355/4885PAX8 3423/4885PTPN1 3538/4885 |
| US-20230133147-A1 | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ACE2, ACE, RNASE1 | TSHR 4072/4885PAX8 4520/4885PTPN1 2933/4885 |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | TSHR 1711/4885PAX8 2411/4885PTPN1 2198/4885 |
| US-20230323363-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | KHK, HNRNPK, HK1 | TSHR 4135/4885PAX8 1876/4885PTPN1 3812/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | TSHR 4247/4885PAX8 772/4885PTPN1 3486/4885 |
| US-11840692-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | TEK, RNASE1, LDLR | TSHR 2165/4885PAX8 2273/4885PTPN1 2395/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | TSHR 2983/4885PAX8 886/4885PTPN1 1294/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | TSHR 510/4885PAX8 1029/4885PTPN1 2596/4885 |
| US-20240209372-A1 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | RNASEH1, IMPDH2, RNASEL | TSHR 4074/4885PAX8 2756/4885PTPN1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.